MedTrace Logo

Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

NCT00201435 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2008-05-20

No results posted yet for this study

Summary

We want to compare Taxol given weekly with Taxotere given every 3 week both in comination with Xeloda. We are going to compare time to treatment failure and quality of life.

Conditions

  • Breast Neoplasm

Interventions

DRUG

Paclitaxel weekly in combination with capecitabine

DRUG

Docetaxel every 3 week in combination with capecitabine

Sponsors & Collaborators

  • Norwegian Breast Cancer Group

    lead OTHER

Principal Investigators

  • Erik Wist, MD, PhD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-01-31
Completion
2008-05-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00201435 on ClinicalTrials.gov